Company attributes
Other attributes
A clinical stage gene and cell therapy company focused on curative intent in solid tumor cancer
Intima Bioscience is conducting a clinical trial initially at the University of Minnesota Masonic Cancer Center with its Molecular and Cell Therapy (MCT) GMP gene and cell therapy manufacturing facility.
Please watch the video below to learn more about our proprietary Checkpoint Cell Therapy, combining two cutting edge therapies for solid tumor cancer in a single clinical trial. A next generation checkpoint inhibitor, CISH with genetically engineered T cell therapy for solid tumors.
A clinical trial to assess the safety and efficacy of genetically-engineered, neoantigen-specific Tumor Infiltrating Lymphocytes (TIL) in which the intracellular immune Checkpoint CISH has been inhibited using CRISPR gene editing for the treatment of Gastro-Intestinal Cancer.
